Acesion Pharma ApS is on a mission to out-license its lead atrial fibrillation (AF) program for the acute setting after success in a Phase II proof-of-concept trial, a move that would enable the firm to concentrate on developing its earlier AF asset for the broader maintenance setting.
The Phase II data mark the validation of the private Danish firm’s first-in-class approach of inhibiting the SK ion channel, a membrane protein that allows potassium cations to cross the cell membrane